U.S. Markets open in 1 hr 25 mins
S&P Futures
4,381.50-30.25(-0.69%)Dow Futures
34,857.00-117.00(-0.33%)Nasdaq Futures
14,869.50-168.25(-1.12%)Russell 2000 Futures
2,223.70-13.80(-0.62%)Crude Oil
73.43-0.19(-0.26%)Gold
1,831.50-4.30(-0.23%)
GlaxoSmithKline plc (GSK.L)
LSE - LSE Delayed Price. Currency in GBp
Add to watchlist
1,413.00+6.60 (+0.47%)
As of 12:50PM BST. Market open.
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 1,406.40 |
| Open | 1,405.60 |
| Bid | 1,412.60 x 0 |
| Ask | 1,413.20 x 0 |
| Day's Range | 1,398.40 - 1,413.40 |
| 52 Week Range | 1,190.80 - 1,619.20 |
| Volume | 2,675,691 |
| Avg. Volume | 7,990,270 |
| Market Cap | 71.095B |
| Beta (5Y Monthly) | 0.40 |
| PE Ratio (TTM) | 13.56 |
| EPS (TTM) | 104.20 |
| Earnings Date | Oct 27, 2021 |
| Forward Dividend & Yield | 0.80 (5.57%) |
| Ex-Dividend Date | May 20, 2021 |
| 1y Target Est | 1,644.50 |
- Editor's PickYahoo Finance Video
We must move towards vaccine mandates to get ahead of Covid-19: Doctor
Dr. Anand Swaminathan, Emergency Medicine Physician in New Jersey, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
- Business Wire
GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps
LONDON, July 29, 2021--GSK announces FDA approval for Nucala (mepolizumab) for use in adults with chronic rhinosinusitis with nasal polyps.
- Zacks
Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised
Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.
© 2021 Verizon Media. All rights reserved.
